Publications & Posters

Interim Analysis of PROMise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib

Download PDF

OPN-6602, an Orally Bioavailable EP300/CBP Bromodomain Inhibitor, Targets Multiple Myeloma through Suppression of IRF4 and MYC

Download PDF

OPN-9840, a non-covalent potent pan-TEAD inhibitor, exhibits single agent efficacy in preclinical malignant mesothelioma models

Download PDF

OPN-6602, a potent dual EP300/CBP bromodomain inhibitor, targets multiple myeloma through concomitant suppression of IRF4 and c-MYC

Download PDF

OPN-6602, a dual EP300/CBP bromodomain inhibitor modulates androgen-driven transcription in mCRPC

Download PDF

Phase IIa Study of PLX2853 in Gynecologic Cancers with known ARID1A mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-resistant epithelial ovarian cancer

https://ascopubs.org/doi/abs/10.1200/PO.23.00235

Phase 1b/2a clinical trial of the oral BET inhibitor PLX2853 as monotherapy for ARID1A mutated gynecologic cancers and in combination with carboplatin for platinum resistant ovarian cancer

Download PDF

Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine

https://doi.org/10.1016/j.leukres.2022.106884

Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft- Versus-Host Disease

https://doi.org/10.3389/fonc.2021.760789

Phase 1b/2a Study of PLX2853, a Small Molecule BET Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma

Download PDF